European Journal of Cancer
Volume 46, Issue 1 , Pages 110-119 , January 2010

18FDG-PET-CT in the follow-up of non-small cell lung cancer patients after radical radiotherapy with or without chemotherapy: An economic evaluation

  • Judith van Loon

      Affiliations

    • Department of Radiation Oncology (Maastro Clinic), GROW Research Institute, Maastricht University Medical Centre+, Maastricht, The Netherlands
    • Corresponding Author InformationCorresponding author: Address: MAASTRO Clinic, Dr. Tanslaan 12, NL-6229 ET Maastricht, The Netherlands. Tel.: +31 88 4455666; fax: +31 88 4455667.
    • ,
  • Janneke P.C. Grutters

      Affiliations

    • Department of Radiation Oncology (Maastro Clinic), GROW Research Institute, Maastricht University Medical Centre+, Maastricht, The Netherlands
    • Department of Health Organization, Policy and Economics, CAPHRI Research Institute, Maastricht University Medical Centre+, Maastricht, The Netherlands
    • ,
  • Rinus Wanders

      Affiliations

    • Department of Radiation Oncology (Maastro Clinic), GROW Research Institute, Maastricht University Medical Centre+, Maastricht, The Netherlands
    • ,
  • Liesbeth Boersma

      Affiliations

    • Department of Radiation Oncology (Maastro Clinic), GROW Research Institute, Maastricht University Medical Centre+, Maastricht, The Netherlands
    • ,
  • Anne-Marie C. Dingemans

      Affiliations

    • Department of Pulmonology, Maastricht University Medical Centre+, Maastricht, The Netherlands
    • ,
  • Gerben Bootsma

      Affiliations

    • Department of Pulmonology, Atrium Medical Centre, Heerlen, The Netherlands
    • ,
  • Wiel Geraedts

      Affiliations

    • Department of Pulmonology, Orbis Medical Centre, Sittard, The Netherlands
    • ,
  • Cordula Pitz

      Affiliations

    • Department of Pulmonology, Laurentius Hospital, Roermond, The Netherlands
    • ,
  • Jean Simons

      Affiliations

    • Department of Pulmonology, St. Jans Hospital, Weert, The Netherlands
    • ,
  • Boudewijn Brans

      Affiliations

    • Department of Nuclear Medicine, Maastricht University Medical Centre+, Maastricht, The Netherlands
    • ,
  • Gabriel Snoep

      Affiliations

    • Department of Radiology, Maastricht University Medical Centre+, Maastricht, The Netherlands
    • ,
  • Monique Hochstenbag

      Affiliations

    • Department of Pulmonology, Maastricht University Medical Centre+, Maastricht, The Netherlands
    • ,
  • Philippe Lambin

      Affiliations

    • Department of Radiation Oncology (Maastro Clinic), GROW Research Institute, Maastricht University Medical Centre+, Maastricht, The Netherlands
    • ,
  • Dirk De Ruysscher

      Affiliations

    • Department of Radiation Oncology (Maastro Clinic), GROW Research Institute, Maastricht University Medical Centre+, Maastricht, The Netherlands

Received 12 October 2009 ,Accepted 29 October 2009.

References 

  1. Rubins J, Unger M, Colice GL. Follow-up and surveillance of the lung cancer patient following curative intent therapy: ACCP evidence-based clinical practice guideline (2nd edition). Chest. 2007;132(3 Suppl.):355S–367S
  2. Mac Manus MP, Hicks RJ, Matthews JP, et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol. 2003;21(7):1285–1292
  3. Mac Manus MP, Hicks RJ, Matthews JP, et al. Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure. Lung cancer. 2005;49(1):95–108
  4. Patz EF, Connolly J, Herndon J. Prognostic value of thoracic FDG PET imaging after treatment for non-small cell lung cancer. AJR Am J Roentgenol. 2000;174(3):769–774
  5. van Loon J, Grutters J, Wanders R, Boersma L, Oellers M, Dingemans AM, et al. Follow-up with 18FDG-PET-CT after radical radiotherapy with or without chemotherapy allows the detection of potentially curable progressive disease in non-small cell lung cancer patients: a prospective study. Eur J Cancer. 2009;45(4):588–595
  6. Drummond MF, Sculpher MJ, Torrance GW, O’brien B, Stoddart GL. Methods for economic evaluation of health care programmes. Oxford: Oxford University Press; 2005;
  7. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13(4):322–338
  8. Sugimura H, Yang P. Long-term survivorship in lung cancer: a review. Chest. 2006;129(4):1088–1097
  9. Wingo PA, Ries LA, Parker SL, Heath CW. Long-term cancer patient survival in the United States. Cancer Epidemiol Biomarkers Prev. 1998;7(4):271–282
  10. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18(10):2095–2103
  11. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22(9):1589–1597
  12. Okamoto Y, Murakami M, Yoden E, et al. Reirradiation for locally recurrent lung cancer previously treated with radiation therapy. Int J Radiat Oncol Biol Phys. 2002;52(2):390–396
  13. Tanvetyanon T, Robinson LA, Schell MJ, et al. Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis. J Clin Oncol. 2008;26(7):1142–1147
  14. Murillo JR, Koeller J. Chemotherapy given near the end of life by community oncologists for advanced non-small cell lung cancer. Oncologist. 2006;11(10):1095–1099
  15. Guidelines for pharmaco-economic research. Diemen: Health Care Insurance Board; 2006.
  16. NHS . Nice guideline costing statement: erlotinib for the treatment of NSCLC. National Institute for Clinical Excellence; 2008;
  17. Kommer GSL, Polder J. Risicosolidariteit en Zorgkosten. Zoetermeer: Raad voor de Volksgezondheid en Zorg; 2005;
  18. Trippoli S, Vaiani M, Lucioni C, Messori A. Quality of life and utility in patients with non-small cell lung cancer. Quality-of-life Study Group of the Master 2 Project in pharmacoeconomics. Pharmacoeconomics. 2001;19(8):855–863
  19. Dancey J, Shepherd FA, Gralla RJ, Kim YS. Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial. Lung cancer. 2004;43(2):183–194
  20. Sensible and sustainable care (in Dutch). Zoetermeer; 2006.
  21. Briggs ACK, Sculpher M. Decision modelling for health economic evaluation. Oxford University Press; 2006;
  22. Weinstein MC. Recent developments in decision-analytic modelling for economic evaluation. Pharmacoeconomics. 2006;24(11):1043–1053
  23. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ. 2001;10(8):779–787
  24. Claxton K, Sculpher M, Drummond M. A rational framework for decision making by the National Institute for Clinical Excellence (NICE). Lancet. 2002;360(9334):711–715
  25. Edelman MJ, Meyers FJ, Siegel D. The utility of follow-up testing after curative cancer therapy. A critical review and economic analysis. J Gen Intern Med. 1997;12(5):318–331
  26. Shih YC, Halpern MT. Economic evaluations of medical care interventions for cancer patients: how, why, and what does it mean?. CA Cancer J Clin. 2008;58(4):231–244
  27. Grutters JP, Joore MA, van der Horst F, Stokroos RJ, Anteunis LJ. Decision-analytic modeling to assist decision making in organizational innovation: The case of shared care in hearing aid provision. Health Serv Res. 2008;
  28. Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn’t it increase at the rate of inflation?. Arch Intern Med. 2003;163(14):1637–1641
  29. Buxton MJ. Economic evaluation and decision making in the UK. Pharmacoeconomics. 2006;24(11):1133–1142
  30. Benamore R, Shepherd FA, Leighl N, et al. Does intensive follow-up alter outcome in patients with advanced lung cancer?. J Thorac Oncol. 2007;2(4):273–281
  31. Westeel V, Lebitasy MP, Mercier M, et al. IFCT-0302 trial: randomised study comparing two follow-up schedules in completely resected non-small cell lung cancer. Rev Mal Respir. 2007;24(5):645–652
  32. Khan AJ, et al. Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC). Radiother Oncol. 2006;81(2):163–167
  33. Oostenbrink JBC, Koopmanschap M, Rutten F. In: C.v. Zorgverzekeringen, editor. Handleiding voor kostenonderzoek, methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg, 2004.
  34. Tyldesley S, et al. Estimating the need for radiotherapy for lung cancer: an evidence-based, epidemiologic approach. Int J Radiat Oncol Biol Phys. 2001;49(4):973–985

PII: S0959-8049(09)00815-6

doi: 10.1016/j.ejca.2009.10.028

European Journal of Cancer
Volume 46, Issue 1 , Pages 110-119 , January 2010

Article Tools

* Image Usage & Resolution